A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Abroad (travel likely)RecruitingPHASE3

Conditions

Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Yazhou Zhao) · yuhuan_jiao@sinocelltech.com · 13001958778

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Cognitive Dysfunction · Lewy Body Disease · Synucleinopathies

Abroad (travel likely)RecruitingPHASE2

Chandler, United States · Scottsdale, United States

The Eplontersen Pregnancy and Lactation Outcomes Study

Transthyretin Amyloidosis

Abroad (travel likely)Recruiting

Frankfurt, Germany

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Relapsed/Refractory Systemic Light Chain Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Denver, United States

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Hereditary Transthyretin-mediated (hATTR) Amyloidosis · Polyneuropathy

Abroad (travel likely)Recruiting

Iowa City, United States · Nantes, France